Advertisement

PCP43 - HEALTH IMPACT MODELLING (HIM): CONCEPT, APPROACH AND REAL-WORLD DATA NEEDS FOR THE ESTIMATION OF POTENTIAL EFFECTIVENESS PROVIDED BY A PHARMA COMPANY PORTFOLIO

      Objectives: To establish health impact modelling (HIM) concept, and to design and assess the feasibility of the HIM modelling approach and real-world data (RWD) needs for the estimation of potential effectiveness provided by Pfizer Finland portfolio. Methods & results: The HIM concept seeks to convert company turnover into health benefits. Evidence-based PICOSTEPS framework was applied to define the feasibility and RWD needs for the HIM application in their order of importance. {1} Patients: All Finns treated with the prescribed Pfizer Oy pharmaceuticals. {2} Intervention: Pfizer pharmaceuticals available in Finland. Over 2300 patient-intervention pairs (indication based on ICD-9/10, intervention based on Pfizer pharmaceuticals) were defined mainly based on the nationally representative Finnish RWD covering all Finns. {3} Comparator: No intervention (i.e., to establish the potential benefits gained with Pfizer pharmaceuticals). {4} Outcomes: Duration of use (persistence) and potential quality-adjusted life years (QALY) gained. {5} Setting: dynamic modelling based on quarterly RWD. {6} Time: 01/2016–06/2017 without discounting. {7} Effects: Potential persistence based on the quarterly purchase RWD of all new and existing patient-intervention pairs, effectiveness multiplier, and health-related quality of life (HRQoL) based on World Health Organization’s (WHO) or Finnish HRQoL evidence were applied. 64 groups of HRQoL beneficiaries were defined from the WHO evidence and linked to the patient-intervention pairs. {8} Perspective: Societal (WHO) and patient (Finnish HRQoL). {9} Sensitivity: Low and high results based on the 95% HRQoL confidence intervals. Finally, the HIM can produce potential QALY benefits gained based on the Pfizer pharmaceuticals portfolio in Finland. Conclusions: The feasibility of HIM modelling approach is dependent on the availability of needed local and/or locally-applicable RWD. The development of HIM concept, modelling approach and data needs was an important journey that can set migration to the assessment of benefits.